Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Creative Commons Attribution 4.0 International License (CC-BY 4.0)?
No comments here
Why not start the discussion?
Skip to main content
Reviews of "Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"
Reviewers: S Vasan (Henry M Jackson Foundation) | 📘📘📘📘📘 • E Mills (McMaster University) | 📘📘📘📘📘
Published onAug 15, 2022
Reviews of "Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"
To read the original manuscript, click the link above.
Summary of Reviews: This preprint evaluated the effectiveness of ivermectin in shortening symptom duration or preventing hospitalization in people with mild-moderate COVID-19 symptoms. Both reviewers are in agreement that this study provides strong support for its claim that ivermectin does not seem to provide any clinically significant improvement in treatment outcomes.
Reviewer 1 (Sandhya V) | 📘📘📘📘📘
Reviewer 2 (Edward M) | 📘📘📘📘📘
To read the reviews, click the links below.
